According to a study carried out on a mutant APP transgenic mouse model, the rapamycin-mediated inhibition of mTOR can ameliorate Aβ pathology and cognitive dysfunction and either slow down or halt the progression of AD [235]. Here, APP is linked to Alzheimer disease.